Focal Segmental Glomerulosclerosis Drugs Market Analysis: Key Insights on Growth Rates, Trends, and Major Opportunities
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
How has the Focal Segmental Glomerulosclerosis Drugs market grown over the years?
In recent years, the market size for drugs designed for focal segmental glomerulosclerosis has experienced robust growth. It is projected to increase from $15.77 billion in 2024 to $17.08 billion in 2025, showing a compound annual growth rate (CAGR) of 8.3%. The growth observed in the historical period owes to factors such as a rise in disease prevalence, an increasing demand for novel treatments, heightened interest from the pharmaceutical industry, and growing support from government entities.
What Is the forecasted market size and growth rate for the fog computing market?
The pharmaceutical market for focal segmental glomerulosclerosis is projected to witness a significant increase in the coming years. By 2029, it’s expected to hit the $24.87 billion mark, growing at a compound annual rate (CAGR) of 9.8%. This predicted growth for the forecast duration is largely due to factors like research and development expenses, increased spending on healthcare, growing diagnosis and awareness, an aging demographic, and government-backed initiatives and funding. Key trends throughout this period will be technological innovation in drug research and development, a growing clinical trials pipeline, better reimbursement policies for focal segmental glomerulosclerosis treatments, and expanded corporate research infrastructure.
Get your focal segmental glomerulosclerosis drugs market report here!
What are the major factors driving growth in the focal segmental glomerulosclerosis drugs market?
The focal segmental glomerulosclerosis (FSGS) drugs market is anticipated to capitalize on the growing prevalence of kidney infections. Pyelonephritis, a kidney infection that can influence one or both kidneys, is a severe form of urinary tract infection (UTI). FSGS drugs are beneficial in treating kidney diseases. They enhance kidney functionality by managing proteinuria, slowing down kidney damage progression, and bettering the quality of life for kidney disease patients. As of July 2022, the US Department of Health and Human Services’ Centers for Disease Control and Prevention noted that kidney disease affected approximately 15%, or 37 million, US residents. The disease afflicted 12% of people aged 45-64 and 6% of those between 18 and 44 in 2021. Consequently, the expanding rate of kidney infections is behind the growth of the FSGS market. The surge in healthcare spending is projected to foster the growth of the focal segmental glomerulosclerosis (FSGS) drugs market. Healthcare expenditure pertains to the total monetary allocation for healthcare services and related commodities and activities within a particular healthcare system or economy during a specific time. Augmented healthcare spending can contribute to the creation and availability of FSGS drugs. It can enhance research funding and clinical trials, thereby bettering drugs production. The Canadian Institute for Health Information, a Canada-based health information institute, reported in November 2023 that Canada’s total health expenditure is expected to hit $344 billion in 2023, amounting to $8,740 per person. This represents a 2.8% increase from the previous year, which saw a mere 1.5% increase in health spending in 2022, showcasing a significant rebound in healthcare investment. Thus, escalating healthcare expenditures bolster the growth of the FSGS drugs market.
What key areas define the segmentation of the global focal segmental glomerulosclerosis drugs Market?
The focal segmental glomerulosclerosis drugs market covered in this report is segmented –
1) By Type: Losmapimod, SHP-627, Sparsentan, TM-5484, Other Types
2) By Treatment: Corticosteroids, Immunosuppressive Drugs, Angiotensin Converting Enzymes (ACE) Inhibitors, A.R. Blockers, Diuretics, Other Treatments
3) By Route of Administration: Oral, Parenteral
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12866&type=smp
What are the top market players propelling the growth of the focal segmental glomerulosclerosis drugs industry?
Major companies operating in the focal segmental glomerulosclerosis drugs market are Pfizer Inc., Johnson and Johnson Ltd., F. Hoffmann-La Roche AG, Bayer AG, Novartis AG, Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca PLC, Fresenius Kabi Ltd., GSK PLC, Medtronic Plc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Astellas Pharma Inc., Otsuka Pharmaceutical Co. Ltd., Mylan N.V., B. Braun Melsungen AG, Hikma Pharmaceuticals PLC, Alexion Pharmaceuticals, Wockhardt, Travere Therapeutics, Aurinia Pharmaceuticals Inc., Omeros Corporation, Dimerix Ltd., Goldfinch Bio.
What are the key trends shaping the future of the focal segmental glomerulosclerosis drugs market?
Top firms in the focal segmental glomerulosclerosis (FSGS) market are prioritizing product development and innovation to produce trustworthy products for clients and solidify their standing in the market. For instance, US-based biopharmaceutical company, Travere Therapeutics, launched FILSPARI for FSGS in February 2023, and it received approval from the US-based federal agency, the Food and Drug Administration (FDA). It’s an orally consumed treatment for IgA nephropathy (IgAN) and marks the debut of the sole non-immunosuppressive solution for reducing proteinuria in IgAN, a rare kidney disease. Furthermore, FILSPARI has been awarded the orphan drug status in the United States and Europe for treating IgAN and focal segmental glomerulosclerosis (FSGS).
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12866
What regions are dominating the focal segmental glomerulosclerosis drugs market growth?
North America was the largest region in the focal segmental glomerulosclerosis drugs market in 2024. The regions covered in the focal segmental glomerulosclerosis (FSGS) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Browse Through More Similar Reports By The Business Research Company:
Kidney Dialysis Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/kidney-dialysis-global-market-report
Artificial Kidney Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/artificial-kidney-global-market-report
Diabetic Kidney Disease Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/diabetic-kidney-disease-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
